Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enablex for Nocturia and Sleep in Overactive Bladder
NCT01018225Phase 4Withdrawn
- Sponsor
- Cognitive Research Corporation
- Start
- Nov 2009
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of darifenacin in nocturia, overactive bladder (OAB), sponsored by Cognitive Research Corporation. Planned start Nov 2009; status: withdrawn.
02
Drugs
darifenacin
03
Conditions
nocturiaoveractive bladder (OAB)
Beyond the preview
Go deeper on NCT01018225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01018225.